Surface Oncology Competitors, Revenue and Alternatives
Estimated Revenue & Financials
- Surface Oncology's estimated annual revenue is currently $59.4M per year.
- Surface Oncology received $35.0M in venture funding in January 2015.
- Surface Oncology's estimated revenue per employee is $618,927
- Surface Oncology's total funding is $143M.
- Surface Oncology has 96 Employees.
- Surface Oncology grew their employee count by 26% last year.
- Surface Oncology currently has 4 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Pricing|
|Cell Signaling ...||$89.4M||577||N/A||N/A||N/A|
What Is Surface Oncology?
Surface Oncology is a clinical-stage immuno-oncology company focused on using its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment (TME) for the development of next-generation therapies to help patients suffering with cancer. Recent advances in understanding how the immune system fights cancer has created a first wave of immunotherapies with profound benefits for some patients. These first-generation therapies, or "checkpoint inhibitors", have been groundbreaking, but only a relatively small subset of patients is deriving long-term benefit. We believe that the lack of a broad and sustained clinical response is because these first-generation therapies only target one component of the immunosuppressive TME and a broader, more multi-faceted therapeutic approach is required. Surface is leveraging its deep understanding of TME biology to target factors and cells that suppress patients anti-tumor immune response. Our broad attack on the TME has the potential to convert patients non-responsive cold tumors into immune-active ones. We are committed to developing a pipeline of next-generation immunotherapies that deliver lasting benefits to patients suffering from cancer as quickly as possible. From a discovery perspective, Surface leverages its world-class SAB to identify new targets and takes an aggressive approach towards generating diverse, highly-specific antibodies, which allows our scientists to thoroughly explore the relevant biology. We utilize multiple antibody generation platforms and have established relationships with several best-in-class antibody technology partners. Our antibody discovery approach generates therapeutic-quality antibodies, as well as unique tools to explore the biology of the tumor microenvironment. The company has a strategic collaboration with Novartis and is supported by leading healthcare investors, including Atlas Venture, NEA, F-Prime, Lilly Ventures and Amgen Ventures.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
|Vito Palombella||Chief Scientific Officer|
|Kerry White||Principal Scientist||Email Available|
|Shannon Rourke Devens||Vice President|
|Abhay Patki||Senior Director, Clinical Science||Email Available|
|Kate Sullivan||Senior Manager, Qc And Stability||Email Available|
|Christina Riordan||Senior Director Toxicology||Email Available|
|Devan Moodley||Principal Scientist|
|Chris Beans||Manager, IT Operations||Email Available|
|Caroline Armet||Research Associate/Lab Manager|
|Nicole Carvalho||"i Am Not The Corporate Police...." - Nmc Senior Manager, Qa||Email Available|
Surface Oncology News
CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), today announced Ramy Ibrahim, M.D., will ...
Surface Oncology Inc (NASDAQ:SURF) was the target of a large drop in short interest in the month of July. As of July 31st, there was short ...
CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (SURF), a clinical-stage immuno-oncology company ...
Surface Oncology Funding
Surface Oncology Executive Hires
|2015-05-08||Detlev Biniszkiewicz||President & CEO||Article|
|2016-01-29||Vito J. Palombella||Chief Scientific Officer.||Article|
|2016-12-16||Robert Ross||Chief Medical Officer||Article|
|2017-01-05||Daniel Lynch||Executive Chairman||Article|
|2017-02-08||Jeff Goater||Chief Business Officer||Article|